The International journal of eating disorders · 2013
Zonisamide in the treatment of bulimia nervosa: an open-label, pilot, prospective study.
Клиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guerdjikova Anna I, Blom Thomas J, Martens Brian E, Keck Paul E, McElroy Susan L
Аннотация
OBJECTIVE: To assess preliminarily the effectiveness of zonisamide in bulimia nervosa.
METHOD: This was an open-label, prospective, 12-week, flexible dose study of zonisamide in bulimia nervosa. The primary outcome was binge-purge episode frequency.
RESULTS: Twelve individuals received zonisamide, 10 completed at least one post-baseline evaluation, and six completed the study. Mean dose at endpoint was 420 (SD = 215) mg/day. Zonisamide was associated with significant reductions in frequency of binge-purge episodes and binge-purge days as well as measures of binge eating behavior, purging behavior, clinical severity, obsessive-compulsive features, and depressive symptoms. Weight was unchanged.
DISCUSSION: In this open-label trial, zonisamide was effective in bulimia nervosa, but associated with a high discontinuation rate.
METHOD: This was an open-label, prospective, 12-week, flexible dose study of zonisamide in bulimia nervosa. The primary outcome was binge-purge episode frequency.
RESULTS: Twelve individuals received zonisamide, 10 completed at least one post-baseline evaluation, and six completed the study. Mean dose at endpoint was 420 (SD = 215) mg/day. Zonisamide was associated with significant reductions in frequency of binge-purge episodes and binge-purge days as well as measures of binge eating behavior, purging behavior, clinical severity, obsessive-compulsive features, and depressive symptoms. Weight was unchanged.
DISCUSSION: In this open-label trial, zonisamide was effective in bulimia nervosa, but associated with a high discontinuation rate.